A Phase II Study of Sorafenib in Advanced Uterine Carcinoma / Carcinosarcoma: A Trial of the Chicago, PMH, and California Phase II Consortia

OBJECTIVES: To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma. METHODS: This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine ca...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Huo, Dezheng, Elit, Laurie, Knost, James A., Wade, James L., Agamah, Edem, Vokes, Everett E., Fleming, Gini F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2842466/
https://ncbi.nlm.nih.gov/pubmed/20117828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2010.01.013
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items